




RNS

Issue of Equity

[Share this article](#)



Issue of new shares under the SIP and TVR

IDEAGEN PLC

Released 16:46:55 12 November 2021

RNS Number : 2903S
Ideagen PLC
12 November 2021

Ideagen PLC
("Ideagen," "the Company" or the "Group")

Issue of new shares under the Share Incentive Plan and Total Voting Rights

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management Software to highly regulated industries, announces that it has allotted a total of 3,789 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") following the purchase of 3,789 Ordinary Shares by a number of employees under the Company's Share Incentive Plan ("SIP").

Application has been made to the London Stock Exchange for the 3,789 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 18 November 2021.

After Admission, the total number of Ordinary Shares in issue will be 255,351,615 and the total number of voting rights will therefore be 255,351,615. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.

Enquiries:

Ideagen plc **01629 699 100**
Ben Dorks, Chief Executive Officer
Emma Hayes, Chief Financial Officer

finnCap Limited **020 7220 0500**
Henrik Persson/James Thompson (Nomad)
Alice Lane (ECM)

Canaccord Genuity Limited (Joint Broker) **020 7523 8000**
Simon Bridges
Richard Andrews

Numis (Joint Broker) **0207 260 1267**
Simon Willis
Joshua Hughes
Tejas Padalkar

FTI Consulting **020 3727 1000**
Jamie Ricketts
Dwight Burden
Valerija Cymbal
ideagen@fticonsulting.com

About Ideagen plc

Ideagen's software helps companies comply with regulation and manage risk.

Ideagen is a leader in the \$30 billion GRC software market, serving highly regulated industries such as life sciences, healthcare, banking and finance and insurance. Ideagen has made twenty acquisitions to build its market leadership.

More than 6000 organisations use Ideagen's software, including nine of the top 10 UK accounting firms, all of the top aerospace and defence companies and 75% of leading pharmaceutical firms.

Ideagen has a diversified customer base including blue chip, global brands such as Heineken, British Airways, BAE, Aggreko, US Navy, Bank of New York and Johnson Matthey, as well as 250 hospitals across the UK and US.

With over 700 employees Ideagen is headquartered in the UK, listed on the London Stock Exchange AIM market (Ticker: IDEA.L), and has key hubs in the UK, EU, US, Middle East and South East Asia.

For further information please visit www.ideagen.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEDKBBQABDDDBDD

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.